Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study

Review Microbiology

Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?

Patricia J. Simner et al.

Summary: Cefiderocol is a novel siderophore-conjugated cephalosporin that shows activity against multidrug-resistant Gram-negative bacilli. It utilizes a siderophore component to bind iron and enter bacterial cells, leading to cell death. Further clinical studies are needed to determine its effectiveness against other organisms.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

添加到收藏夹

Article Immunology

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Marco Falcone et al.

Summary: In this study, cefiderocol was used to treat patients with bacteremia or ventilator-associated pneumonia caused by drug-resistant strains, showing a 70% clinical success rate and 90% survival rate. However, two patients experienced microbiological failure, highlighting the need for future prospective studies to further evaluate the effectiveness of the treatment.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Microbiology

Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison to Disk Diffusion to Broth Microdilution

C. Paul Morris et al.

Summary: Interpretation of cefiderocol ASTs varies significantly depending on the breakpoints used by CLSI, FDA, and EUCAST. DD offers a convenient alternative approach to BMD methods for cefiderocol AST, except for isolates of Acinetobacter baumannii complex.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology